Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Short Acting Beta Agonist (SABA)
Short Acting Beta Agonist · 1 trial · 1 indication
Biologic treatments for asthma will include mepolizumab (anti-Interleukin \[IL\] 5), omalizumab (anti-immunoglobulin E \[IgE\]), and reslizumab (anti-IL5).
| Arm | Type | Description |
|---|---|---|
| Non-drug interventional group | OTHER | All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants. |
| Name | Type | Description |
|---|---|---|
| Short Acting Beta Agonist (SABA) | DRUG | Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments |
Inclusion Criteria: * At least 12 years of age at study visit. * Participants eligible for enrolment and entry into the study must meet the following definition of severe asthma, which is based on the definition of severe asthma described in the European Respiratory Society/ American Thoracic Socie...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Short Acting Beta Agonist is used in asthma, a respiratory condition. It is a small molecule therapy developed by GSK plc. The clinical program includes a completed Phase 3 study in asthma patients aged 12 years and older. It is an investigational agent in clinical development rather than a marketed product.
Short Acting Beta Agonist is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this small molecule asthma therapy. The asset sits within the respiratory therapeutic area.
Short Acting Beta Agonist is in Phase 3 development for asthma. One Phase 3 trial has been completed, and no trials are currently active. The completed study enrolled 767 participants. The program remains in clinical development.
Short Acting Beta Agonist has been studied in the Phase 3 trial NCT02293265, titled Cross-sectional Study for Identification and Description of Severe Asthma Patients. That trial is completed and enrolled 767 participants across the United States, Australia, Canada, France, Germany, and the United Kingdom.
Yes, Short Acting Beta Agonist is also known as SABA. SABA is the common abbreviation used for this drug name. Both terms refer to the same asthma therapy developed by GSK plc.